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Abstract 
Background: Older adults in care homes have increasingly complex health care needs, and care provision should be 
evidence-based whenever possible. However, recruitment of frail, older people to research is a complex process and 
often results in care home residents being excluded from research participation. This paper draws on the experience 
of setting up a randomised controlled trial to determine the effectiveness of probiotics on antibiotic-associated diar-
rhoea in care home residents [Probiotics for Antibiotic Associated Diarrhoea in Care Homes (PAAD) Study] in Wales.
Findings: Significant challenges were encountered setting up a clinical trial in care homes. There were a number of 
barriers and facilitative factors encountered that were unique to this research setting. The classification of the study 
intervention (a widely available food supplement with a low risk safety profile) as an investigational medicinal prod-
uct, with the associated requirements including obtaining statutory approvals and research governance, had a major 
impact.
Conclusion: The process for setting up a clinical trial of an investigational medicinal product in care homes has been 
more complex and time consuming than the process for setting up an observational study in the same setting, and 
clinical trials in other health care settings. We recommend regulatory changes to ensure approvals processes are more 
proportionate to risk and context, to ensure that care home residents have the opportunity to participate in research 
and are able to help generate much needed evidence to underpin care. Recommendations made may inform future 
research practice.
Trial registration: ISRCTN 25324586.
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Background
An ageing population has resulted in a rise in the number 
of people requiring long term care [1] and those in long 
term care having greater complex health care needs [2]. 
The need for the development of a more structured and 
evidence-based approach to care provision within care 
homes has been recognised [3]. However, recruitment 
of frail, older people to research is a complex process [4]. 
Development of strategies and infrastructures to conduct 
research in older populations in care homes has been 
recommended [5]. These include the creation of ‘research 
ready’ care homes [National Institute Health Research 
Enabling Research in Care Homes (NIHR ENRICH) 
programme] and guidance for all stakeholders on good 
research practice in care home settings [6].
This paper draws on the experience of setting up a 
randomised controlled trial (RCT) to determine the 
effectiveness of probiotics on antibiotic-associated diar-
rhoea in care home residents [Probiotics for Antibiotic 
Associated Diarrhoea in Care Homes (PAAD) Study]. 
The aim was to randomise 400 residents (200 per arm) 
from approximately 24 care homes in South Wales, com-
mencing 2013. We aimed to implement this trial after 
an observational study of antibiotic use and associated 
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diarrhoea in the same setting [7]. Although we did not 
implement the trial because of new emerging data, we 
encountered many specific unique challenges in setting 
up a clinical trial of an investigational medicinal product 
(CTIMP) in this largely research naïve environment that 
resulted in significant challenges and delay. Our experi-




The planned intervention was a probiotic preparation 
(VSL#3) that is commercially available to the general 
public as a food supplement. However, the Medicines and 
Healthcare products Regulatory Agency confirmed that 
its use in this trial was classified as a CTIMP and there-
fore required clinical trial approval. The classification of 
a pragmatic study involving a widely available food sup-
plement with a low risk safety profile as a CTIMP had a 
significant impact. The disparity between the statutory 
authorisations required for an IMP, and the largely absent 
relevant documentation for a product generally char-
acterised as a food supplement, resulted in significant 
delays in conducting the trial.
Recruitment of care homes
Recruitment of care homes as sites was a challenging and 
lengthy process. Care homes can be regarded as ‘commu-
nities of care’ where managers act as ‘gatekeepers’ both 
in terms of access to residents (e.g. to invite participa-
tion in research) and access to health care, and can act 
as a barrier or a facilitator. The degree of autonomy will 
vary greatly in each care home, and the background of 
the manager will also differ greatly (clinical or non-clin-
ical) and experiences of health care or research activity. 
Care home managers were generally supportive about 
conducting research, but required assurances that sup-
port would be provided by the research team, and that 
the additional workload for care home staff would be 
minimised. It was planned to embed research nurses 
in participating care homes to assist with study related 
activities.
The manager then sought agreement from the wider 
community of staff within the care home before agreeing 
to participate. Consent in care homes has been described 
as a two tiered process, where obtaining consent at insti-
tutional/community level is required before progressing 
to consent from individuals [8], described as ‘gaining 
entree’ [9]. The process for recruiting 24 care homes was 
originally expected to take 5 months, this was extended 
to 13  months due to the difficulties outlined. Strategies 
to support the delivery of research in this health care 
setting in England and Scotland, in particular the NIHR 
ENRICH programme supported by local clinical research 
networks (NIHR LCRN), do not currently extend to 
Wales.
Identification of principal investigators
It is a regulatory requirement in the UK that each 
research site has a principal investigator (PI) respon-
sible for the conduct of the trial at the site [10]. Whilst 
the care home manager (if a Registered Nurse) could act 
as PI, the decision whether a subject is eligible for entry 
into a CTIMP is considered to be a medical decision and, 
therefore, must be made by a medically qualified doctor 
in accordance with the regulations [10]. The care home 
resident’s general practitioner (GP) would be responsible 
for assessing eligibility and prescribing the IMP, which 
required the recruitment of GP practices as research sites 
in addition to the care homes themselves.
GP involvement
Responsible clinicians are required to confirm that sub-
jects are eligible to participate in a CTIMP, but not in 
an evaluation of a food supplement. As this was consid-
ered a CTIMP, GPs were required to agree that each care 
home resident who provided consent could participate. 
Several GPs from multiple practices often provide care in 
a single care home. The practical difficulties experienced 
when seeking all relevant GPs’ agreement to participate, 
and the requirements for each practice to be a trial site 
in terms of approvals, good clinical practice (GCP) train-
ing and study-specific training for each GP, proved to be 
a major barrier to conducting the trial. Strategies were 
developed to minimise the burden on GPs and to encour-
age their involvement. This included the availability of 
online GCP training along with drawing up a letter agree-
ment in place of a more comprehensive practice agree-
ment or formal contract.
Ethics approval
Adults lacking capacity may only be included in a 
CTIMP if; (a) similar results are unlikely to be obtained 
with individuals who can provide informed consent 
for themselves; (b) the benefits of administering the 
medicinal product are expected to outweigh risk to the 
participant, and (c) the trial relates directly to a life-
threatening or debilitating condition from which the 
subject suffers [10]. Data obtained from the preced-
ing observational study showed that the majority of 
residents (71%) lacked capacity and that those without 
capacity were significantly more likely to be prescribed 
antibiotics, be more frail, be at greater nutritional risk, 
and more often suffer from antibiotic-associated diar-
rhoea [7]. These data were provided to the Research 
Ethics Committee to support plans to include residents 
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without capacity, as they are most at risk of the adverse 
consequences of antibiotic use and most likely to 
benefit from the study findings. Due to the contin-
ued request for justification of those lacking capacity, 
gaining ethical approval from the South East Wales 
Research Ethics Committee took 4 months. The obser-
vational study, which also involved adults who lacked 
capacity, received ethical approval in 1  month. How-
ever as a non-CTIMP it was governed by the Mental 
Capacity Act 2005.
Research governance
Research governance in care homes is complex due to 
their status as non-NHS institutions and the contrac-
tual and financial arrangements of the resident as either 
self-funding, Local Authority funded or a mix of both 
[11] and they may also receive NHS-funded care. This 
is further complicated by whether the care provider is a 
commercial or non-commercial organisation. The lack 
of clarity regarding responsibility for research govern-
ance for the care homes involved was further clouded by 
the classification of the trial as a CTIMP and that, whilst 
care homes would be the main sites, GP practices would 
also be sites but are NHS organisations. The study also 
covered a number of health boards and local authorities 
that resulted in each of these organisations conducted 
their own approvals process. Resources are available 
which provide information and advice about conduct-
ing research in care homes [12], whilst research govern-
ance toolkits have been developed in other independent 
health and social care settings [13] which could be fur-
ther developed for this setting.
Indemnity
Issues arose around the indemnity requirements for care 
homes participating in research, particularly CTIMPs, 
as non-NHS sites. Research potentially exposes partici-
pants and researchers to risks of harm, and indemnity is 
required to protect against the effects of such risks [6]. 
Indemnity for research activity in the UK is provided by 
the Study Sponsor who would be liable for any non-neg-
ligent harm resulting from activity conducted in accord-
ance with the Study Protocol. However, any negligence 
on behalf of the site (such as giving an incorrect dose) 
would not be covered by this indemnity and, although 
the likelihood of a claim arising out of the trial was small, 
it would have had to be covered by the site insurance. The 
NHS is vicariously liable through NHS Indemnity; how-
ever non-NHS researchers are obliged to make their own 
arrangements. A requirement for additional indemnity 
further impacted on the time required for setting up a 
CTIMP in the care home sector and may impact on care 
homes agreeing to participate. Indemnity costs should be 
included in funding applications for future research in 
care homes.
Conclusion
The process for setting up a clinical trial in care homes 
has been more complex and time consuming than the 
process for setting up an observational study in the same 
setting, and clinical trials in other health care settings. 
Information and advice is available for research teams 
conducting research with the care home sector, how-
ever there is limited practical support available outside 
England and Scotland. Ethical concerns regarding the 
inclusion of older adults lacking capacity, combined with 
non-NHS research governance and the multiple layers of 
permissions and agreement required at each level of the 
process are challenging.
Strategies must be developed to streamline the approv-
als process and minimise the impact to ensure that an 
evidence-based approach to health care provision within 
care homes can be developed. Further consideration 
needs to be given in low risk CTIMP on regulatory inter-
pretation, over and above monitoring, to ensure pro-
cesses are more proportionate to risk and context. The 
incoming clinical trials regulation [14] may address some 
of these issues by recognising the importance of improv-
ing treatments for vulnerable groups such as frail or older 
adults and the introduction of ‘low-intervention clinical 
trials’. This may increase the amount of research involving 
this, and other, vulnerable populations that already expe-
rience health inequalities as a result of a lack of evidence-
based health care. Unless the situation changes, care 
home residents will continue to be declined participation 
and potential benefit from trials of low risk interventions.
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